NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Price, News & Analysis $1.86 +0.02 (+1.09%) Closing price 04:00 PM EasternExtended Trading$1.84 -0.02 (-0.81%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ProQR Therapeutics Stock (NASDAQ:PRQR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProQR Therapeutics alerts:Sign Up Key Stats Today's Range$1.79▼$1.9050-Day Range$1.67▼$2.4352-Week Range$1.33▼$3.10Volume741,853 shsAverage Volume739,503 shsMarket Capitalization$195.97 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingModerate Buy Company Overview ProQR Therapeutics N.V. (NASDAQ: PRQR) is a biotechnology company focused on developing RNA-based medicines for genetic and other serious diseases. The company’s research platform is designed to modify RNA and potentially correct disease-causing genetic defects without permanently changing a patient’s DNA. ProQR has primarily pursued treatments for inherited retinal disorders and other conditions affecting the eye. Its pipeline has included investigational RNA therapies such as sepofarsen, developed for Leber congenital amaurosis type 10, and ultevursen, developed for Usher syndrome type 2A. The company’s programs and development priorities may change as clinical testing and regulatory evaluation progress. Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR operates internationally through research, development and strategic collaboration activities. Its RNA-editing technology has also supported partnerships with larger pharmaceutical companies, including Eli Lilly. Daniel A. de Boer has served as the company’s chief executive officer and co-founder.AI Generated. May Contain Errors. Read More ProQR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScorePRQR MarketRank™: ProQR Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 99th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingProQR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialProQR Therapeutics has a consensus price target of $7.50, representing about 304.3% upside from its current price of $1.86.Amount of Analyst CoverageProQR Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ProQR Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.45) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ProQR Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.55% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 2.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently increased by 10.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentProQR Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ProQR Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for PRQR on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows4 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of ProQR Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $988,500.00 in company stock, which represents 0.5058% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $988,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by Institutions32.65% of the stock of ProQR Therapeutics is held by institutions.Read more about ProQR Therapeutics' insider trading history. Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRQR Stock News HeadlinesProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease TreatmentSeptember 10, 2026 | finance.yahoo.comProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026September 9, 2026 | globenewswire.comIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military protection against Iran-backed forces. An anonymous source says that protection was only one side of an extraordinary bargain, with the other side potentially worth trillions of dollars to America. Addison Wiggin traced the deal linking Trump, Iran, and this government, and says the headlines look very different once you know who is involved.September 16 at 1:00 AM | Banyan Hill Publishing (Ad)ProQR to Participate in Upcoming Investor Conferences in September 2026September 2, 2026 | globenewswire.comProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other CatalystsAugust 21, 2026 | seekingalpha.comProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 ResultsAugust 15, 2026 | theglobeandmail.comProQR posts Q2 2026 results as Axiomer RNA editing gains first clinical validationAugust 15, 2026 | theglobeandmail.comProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline MilestonesAugust 13, 2026 | quiverquant.comQSee More Headlines PRQR Stock Analysis - Frequently Asked Questions How have PRQR shares performed this year? ProQR Therapeutics' stock was trading at $2.02 at the start of the year. Since then, PRQR stock has decreased by 8.2% and is now trading at $1.8550. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics N.V. (NASDAQ:PRQR) released its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. The biopharmaceutical company earned $10 million during the quarter, compared to the consensus estimate of $4.56 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 73.83% and a negative net margin of 223.51%. When did ProQR Therapeutics IPO? ProQR Therapeutics (PRQR) raised $90 million in an initial public offering on Thursday, September 18th 2014. The company issued 7,500,000 shares at a price of $11.00-$13.00 per share. Who are ProQR Therapeutics' major shareholders? ProQR Therapeutics' top institutional investors include RFG Advisory LLC (0.06%). Insiders that own company stock include Boer Daniel Anton De and Bart Filius. View institutional ownership trends. How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProQR Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE). Company Calendar Last Earnings8/13/2026Today9/16/2026Investor update9/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 4 weeks, PRQR's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRQR CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees166Year Founded2012Price Target and Rating Average Price Target for ProQR Therapeutics$7.50 High Price Target$10.00 Low Price Target$3.00 Potential Upside/Downside+303.2%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.73 million Net Margins-223.51% Pretax Margin-229.40% Return on Equity-73.83% Return on Assets-35.14% Debt Debt-to-Equity RatioN/A Current Ratio3.49 Quick Ratio3.49 Sales & Book Value Annual Sales$17.99 million Price / Sales10.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book3.51Miscellaneous Outstanding Shares105,360,000Free Float96,513,000Market Cap$195.97 million OptionableOptionable Beta0.06 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PRQR) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredTSM just handed Trump's secretive AI project $100 billion — See this before September 29Taiwan Semiconductor just pledged another $100 billion to US chip manufacturing, bringing its total US investm...InvestorPlace | SponsoredIran War SHOCK: My Source Told Me to Watch for ThisA Middle Eastern government just asked Trump for military help against Iran-backed forces. One analyst says...Banyan Hill Publishing | SponsoredBlackRock, Vanguard... and a 2.8 million-share buybackManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
